420 Magazine Background

EndoCannabinoids In Endocrine And Related Tumours

Julie Gardener

New Member
Maurizio Bifulco, Anna Maria Malfitano, Simona Pisanti and Chiara Laezz
Dipartimento di Scienze Farmaceutiche, Universita` di Salerno, 84084 Fisciano (Salerno), Ital
Endocrine-Related Cancer (2008)


Abstract

The ‘endocannabinoid system’, comprising the cannabinoid CB1 and CB2 receptors, their endogenous ligands, endocannabinoids and the enzymes that regulate their biosynthesis and degradation, has drawn a great deal of scientist attention during the last two decades. The endocannabinoid system is involved in a broad range of functions and in a growing number ofphysiopathological conditions. Indeed, recent evidence indicates that endocannabinoids influence the intracellular events controlling the proliferation of numerous types of endocrine and relate cancer cells, thereby leading to both in vitro and in vivo antitumour effects. In particular, they areable to inhibit cell growth, invasion and metastasis of thyroid, breast and prostate tumours. Thechief events of endocannabinoids in cancer cell proliferation are reported highlighting thecorrespondent signalling involved in tumour processes: regulation of adenylyl cyclase, cyclicAMP-protein kinase-A pathway and MEK-extracellular signal-regulated kinase signalling cascade.
Endocrine-Related Cancer (2008) 15 391–40

Source with Charts, Graphs and Links: Endocrine-Related Cancer
 
Top Bottom